

# Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021

## -- Conference Call Scheduled for Thursday, February 11, 2021, at 8:30 a.m. ET --

NEWTON, Mass., Feb. 4, 2021 /[PRNewswire](#)/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 11, 2021. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, February 11, 2021, to discuss the financial results and other company updates.

To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, <http://investors.karyopharm.com/events-presentations>. An archived webcast will be available on the Company's website approximately two hours after the event.

## About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit [www.karyopharm.com](http://www.karyopharm.com).

SOURCE Karyopharm Therapeutics Inc.

For further information: CONTACTS: Investors:, Karyopharm Therapeutics Inc., Ian Karp, Senior Vice President, Investor and Public Relations, 857-297-2241 | [ikarp@karyopharm.com](mailto:ikarp@karyopharm.com); Media, 720 Strategies, Andrew Lee, [andrew.lee@720strategies.com](mailto:andrew.lee@720strategies.com)

---

<https://investors.karyopharm.com/2021-02-04-Karyopharm-to-Report-Fourth-Quarter-and-Full-Year-2020-Financial-Results-on-February-11-2021>